ycliper

Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон

Видео с ютуба Samuel Oschin Comprehensive Cancer Institute

Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPC

Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPC

Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patients

Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patients

Robert Figlin, MD, discusses sequencing when treating metastatic RCC patients

Robert Figlin, MD, discusses sequencing when treating metastatic RCC patients

Robert Figlin, MD, offers his opinion on interesting abstracts at ASCO 2017 related to RCC

Robert Figlin, MD, offers his opinion on interesting abstracts at ASCO 2017 related to RCC

Robert Figlin, MD, explains how checkpoint inhibitors are changing the way RCC is treated

Robert Figlin, MD, explains how checkpoint inhibitors are changing the way RCC is treated

Robert Figlin, MD, speculates on the changing landscape of RCC treatment

Robert Figlin, MD, speculates on the changing landscape of RCC treatment

Dr. Figlin on TKI Therapy Options in Renal Cell Carcinoma

Dr. Figlin on TKI Therapy Options in Renal Cell Carcinoma

7/16/2018 - Session 1: Theodorescu

7/16/2018 - Session 1: Theodorescu

Dr. Figlin on Ongoing ADAPT Trial for mRCC

Dr. Figlin on Ongoing ADAPT Trial for mRCC

Robert A. Figlin, MD, considers combination I-O and TKIs indicated for the treatment of 1st line RCC

Robert A. Figlin, MD, considers combination I-O and TKIs indicated for the treatment of 1st line RCC

Roadmap to Resiliency: Medical Perspectives and Strategies for Managing Distress

Roadmap to Resiliency: Medical Perspectives and Strategies for Managing Distress

Constantine Tam, MD & Robert Figlin, MD discuss progress in Waldenstrom’s Macroglobulinemia & ASCO20

Constantine Tam, MD & Robert Figlin, MD discuss progress in Waldenstrom’s Macroglobulinemia & ASCO20

Robert A. Figlin, MD, on I-O & TKIs available and indicated for the treatment of 2nd line RCC

Robert A. Figlin, MD, on I-O & TKIs available and indicated for the treatment of 2nd line RCC

Dr. Mita on Emergence of Checkpoint Inhibitors SCLC

Dr. Mita on Emergence of Checkpoint Inhibitors SCLC

Women's Cancer Research Institute - Cedars-Sinai Medical Center

Women's Cancer Research Institute - Cedars-Sinai Medical Center

Robert A. Figlin, MD, regarding the role of systemic therapy in oligometastatic RCC

Robert A. Figlin, MD, regarding the role of systemic therapy in oligometastatic RCC

Pink Party 2014

Pink Party 2014

Every Step of the Cancer Journey | Joanne, Cedars-Sinai

Every Step of the Cancer Journey | Joanne, Cedars-Sinai

A Man, An Idea, A Mission - David Kulber, MD| Cedars-Sinai

A Man, An Idea, A Mission - David Kulber, MD| Cedars-Sinai

Options for Esophageal Cancer Patients | Cedars-Sinai

Options for Esophageal Cancer Patients | Cedars-Sinai

Следующая страница»

© 2025 ycliper. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]